Finance

Lists
Why is CRBP down 11.29%?
Dive Deeper
CRBP:NASDAQ
Corbus Pharmaceuticals Holdings Inc
$2.44
-11.29%
(-0.31) 1D
$2.44
0.00% (0.00)
After hours
Closed: Nov 19, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRBP...
Open
$2.72
High
$2.88
Low
$2.42
Mkt. cap
50.09M
Avg. vol.
1.07M
Volume
660.43K
52-wk high
$12.88
52-wk low
$2.42
EPS
-$6.09
Beta
2.80
Shares outstanding
20.61M
No. of employees
36
Open
$2.72
High
$2.88
Low
$2.42
Mkt. cap
50.09M
Avg. vol.
1.07M
Volume
660.43K
52-wk high
$12.88
52-wk low
$2.42
EPS
-$6.09
Beta
2.80
Shares outstanding
20.61M
No. of employees
36
News stories
From web sources and news partners
About Corbus Pharmaceuticals Holdings Inc
CEO-
Employees36
FoundedJan 1, 2009
Headquarters-
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 6 analysts giving stock ratings to CRBP in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for CRBP in the last 3 months.
Highest
Current $2.44
$38.00 (+1,460.57%)
Average
$31.80 (+1,205.95%)
Lowest
$23.00 (+844.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$35.00
+1,337.4%
11/16/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$23.00
+844.6%
11/12/2026
Brian Abrahams
RBC Capital
Buy
Reiterated
$33.00
+1,255.2%
11/10/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$30.00
+1,132%
09/15/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
09/14/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
$38.00
+1,460.6%
09/14/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$48.00
+1,871.3%
08/07/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$48.00
+1,871.3%
08/07/2026
Paul Jeng
Guggenheim
Buy
Maintained
$45.00
+1,748%
06/02/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$38.00
+1,460.6%
05/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
$33.00
+1,255.2%
05/12/2026
Unknown Analyst
B. Riley Securities
Buy
Reiterated
$28.00
+1,049.9%
04/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
18.41M
19.82M
31.18M
34.25M
Cost of revenue
18.41M
19.82M
31.18M
34.25M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.56M
4.48M
5.02M
4.58M
Operating expense
3.56M
4.48M
5.02M
4.58M
Total operating expenses
21.97M
24.30M
36.19M
38.82M
Operating income
-21.97M
-24.30M
-36.19M
-38.82M
Other non operating income
-1.10M
-67.00K
-11.00K
-8.00K
EBT including unusual items
-20.56M
-22.97M
-35.04M
-37.75M
EBT excluding unusual items
-21.66M
-22.97M
-35.04M
-37.75M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.56M
-22.97M
-35.04M
-37.75M
Net profit margin
-
-
-
-
Earnings per share
-1.25
-1.23
-1.81
-1.81
Interest and investment income
1.41M
1.40M
1.16M
1.08M
Interest expense
-
-
-
-
Net interest expenses
1.41M
1.40M
1.16M
1.08M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.92M
-24.26M
-36.14M
-38.77M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps